Sovilnesib
Based on 2 publication(s) in Google Scholar
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 2410796-79-9
- Formule: C26H34F2N6O4S
- Masse moléculaire:564.65
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Anti-Lung Cancer Compound Library
HY-L075
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) Sovilnesib
MoreVoir tous les produits spécifiques à Isoform Kinesin
More
Activité biologique
KIF18A[1]
Sovilnesib (AMG 650; 0-10 pM; 96 and 144 h; cancer cell lines) has anti-proliferative activity and inhibits tumor cell growth in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cancer cell lines
-
Concentration:0-10 pM
-
Incubation Time:96 and 144 hours
-
Result:Inhibited tumor cell growth in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice without thymus with OVCAR-3 xenografts
-
Dosage:10, 30, and 100 mg/kg
-
Administration:Oral administration; daily, for 45 days
-
Result:Had antitumor efficacy in a dose-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2410796-79-9
-
Appearance Solid
-
Masse moléculaire 564.65
-
Formule C26H34F2N6O4S
-
Color White to off-white
-
SMILES
O=C(NC1=NC(N2CCC(F)(F)CC2)=NC(C)=C1)C3=CC=C(NS(=O)(CCO)=O)C=C3N(CC4)CCC54CC5
-
Synonyms
AMG 650
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
bioRxiv
2025 Feb 24:2025.02.19.638911. PMID: 40060568
Solvant et solubilité
DMSO : 100 mg/mL (177.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.43 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7710 mL | 8.8550 mL | 17.7101 mL | 44.2752 mL |
| 5 mM | 0.3542 mL | 1.7710 mL | 3.5420 mL | 8.8550 mL | |
| 10 mM | 0.1771 mL | 0.8855 mL | 1.7710 mL | 4.4275 mL | |
| 15 mM | 0.1181 mL | 0.5903 mL | 1.1807 mL | 2.9517 mL | |
| 20 mM | 0.0886 mL | 0.4428 mL | 0.8855 mL | 2.2138 mL | |
| 25 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.7710 mL | |
| 30 mM | 0.0590 mL | 0.2952 mL | 0.5903 mL | 1.4758 mL | |
| 40 mM | 0.0443 mL | 0.2214 mL | 0.4428 mL | 1.1069 mL | |
| 50 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8855 mL | |
| 60 mM | 0.0295 mL | 0.1476 mL | 0.2952 mL | 0.7379 mL | |
| 80 mM | 0.0221 mL | 0.1107 mL | 0.2214 mL | 0.5534 mL | |
| 100 mM | 0.0177 mL | 0.0886 mL | 0.1771 mL | 0.4428 mL |
Sovilnesib Related Classifications
HY-132840 Related Classifications
Powered by Bioz